82VS

Enabling founders, operators, and investors in building the most capital efficient biotech companies

Revolutionizing drug discovery with a unique venture approach

82VS is a venture studio that builds capital efficient, asset focused drug companies by providing unique access to Alloy Therapeutics’ robust suite of discovery platforms and services across antibodies, bispecifics, TCR mimics, and genetic medicines.

Explore our portfolio

We partner and co-build

We collaborate with our ecosystem of partners through every stage of company creation, drug discovery, and development. We are a valuable partner to academics, entrepreneurs, pharma, and VC’s.

We provide access to industry leading technologies

As the first venture studio embedded within an innovative platform and service provider, our companies benefit from Alloy’s continual investments in discovery technologies and enabling services – all at generous, flexible terms.

We build asset centric drug companies with incredible capital efficiency

Our companies leverage the platforms and services of Alloy Therapeutics to accelerate asset creation without being burdened by the cost of developing and maintaining their own platforms.

We fuel entrepreneurial success from concept to Series A

De-risk early stage company creation with our expert support in strategy, legal services, R&D funding, and partnerships that ultimately accelerates your path to Series A financing.

We are a group of operators, dealmakers, and scientists who collaborate across the biotech ecosystem to build with exceptional founders, investors, and partners.

Meet our team